Quintiles’ Prime Site programme expands into Asia to accelerate clinical development
Biopharmaceutical firm Quintiles has agreed a clinical research partnership with the University Malaya Medical Centre (UMMC) as part of its Prime Site programme, an initiative focused on accelerating the development of new medicines. The UMMC is Quintiles’ first Prime Site in Asia, adding to four sites in the US (Washington Hospital Centre and Southern California Permanente Medical Group), Europe (Queen Mary’s College, London) and Africa (University of Pretoria, South Africa).
‘The University Malaya Medical Centre is an ideal partner for us because of its experience in conducting clinical research, its access to substantial patient populations and its clinical expertise across multiple therapeutic areas,’ said Quintiles’ Christopher Cabell.
Professor Dato' Ikram Shah bin Ismail, director of the University Malaya Medical Centre, added: ‘We believe this partnership with Quintiles will serve as an impetus for UMMC to achieve greater efficiencies in conducting clinical trials. By enhancing the efficacy, productivity and quality of clinical research at UMMC, we will ultimately propel the advancement of medical practice in improving human health.’
Quintiles opened its first office in the Asia-Pacific region in 1993. The company now has more than 20 offices in 14 countries throughout the region and a regional headquarters in Singapore. Since 1993, Quintiles has conducted more than 1,300 studies involving 9,000 sites and more than 185,000 patients in the region.